To date, there is still on-going research about Zepbound, but according to certain studies it may indeed proven as an effective treatment for obesity and diabetes
Thyroid, 2020;30(10), 1440-1450.7 Kubiak M, Wiatr K, Kowalczyk A, Grecki R, Gajewska D, Sobieska M
But if youre focused on tirzepatide and want a team that stays in touch, Emerge is a standout
In a 2025 report on the lidERA breast cancer trial, giredestrant reduced any recurrence by 30% and distant or metastatic recurrence by 31% versus tamoxifen or an aromatase inhibitor, with 92.4% recurrence-free survival at three years compared with 89.6% for standard hormonal therapy, according to Breastcancer.org's report on the lidERA trial
Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis